Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 25

1.

Treatment Patterns and Health Outcomes in Platinum-Refractory or Platinum-Resistant Ovarian Cancer: A Retrospective Medical Record Review.

Parikh R, Kurosky SK, Udall M, Chang J, Cappelleri JC, Doherty JP, Kaye JA.

Int J Gynecol Cancer. 2018 May;28(4):738-748. doi: 10.1097/IGC.0000000000001222.

PMID:
29538247
2.

Impact of a planned dose interruption of dacomitinib in the treatment of advanced non-small-cell lung cancer (ARCHER 1042).

Kim DW, Garon EB, Jatoi A, Keefe DM, Lacouture ME, Sonis S, Gernhardt D, Wang T, Giri N, Doherty JP, Nadanaciva S, O'Connell J, Sbar E, Cho BC.

Lung Cancer. 2017 Apr;106:76-82. doi: 10.1016/j.lungcan.2017.01.021. Epub 2017 Feb 1.

3.

A phase II study (ARCHER 1042) to evaluate prophylactic treatment of dacomitinib-induced dermatologic and gastrointestinal adverse events in advanced non-small-cell lung cancer.

Lacouture ME, Keefe DM, Sonis S, Jatoi A, Gernhardt D, Wang T, Doherty JP, Giri N, Nadanaciva S, O'Connell J, Sbar E, Piperdi B, Garon EB.

Ann Oncol. 2016 Sep;27(9):1712-8. doi: 10.1093/annonc/mdw227. Epub 2016 Jun 10.

4.

Functional and molecular characterisation of EO771.LMB tumours, a new C57BL/6-mouse-derived model of spontaneously metastatic mammary cancer.

Johnstone CN, Smith YE, Cao Y, Burrows AD, Cross RS, Ling X, Redvers RP, Doherty JP, Eckhardt BL, Natoli AL, Restall CM, Lucas E, Pearson HB, Deb S, Britt KL, Rizzitelli A, Li J, Harmey JH, Pouliot N, Anderson RL.

Dis Model Mech. 2015 Mar;8(3):237-51. doi: 10.1242/dmm.017830. Epub 2015 Jan 29.

5.

Dacomitinib versus erlotinib in patients with advanced-stage, previously treated non-small-cell lung cancer (ARCHER 1009): a randomised, double-blind, phase 3 trial.

Ramalingam SS, Jänne PA, Mok T, O'Byrne K, Boyer MJ, Von Pawel J, Pluzanski A, Shtivelband M, Docampo LI, Bennouna J, Zhang H, Liang JQ, Doherty JP, Taylor I, Mather CB, Goldberg Z, O'Connell J, Paz-Ares L.

Lancet Oncol. 2014 Nov;15(12):1369-78. doi: 10.1016/S1470-2045(14)70452-8. Epub 2014 Oct 15.

PMID:
25439691
6.

The promotion of breast cancer metastasis caused by inhibition of CSF-1R/CSF-1 signaling is blocked by targeting the G-CSF receptor.

Swierczak A, Cook AD, Lenzo JC, Restall CM, Doherty JP, Anderson RL, Hamilton JA.

Cancer Immunol Res. 2014 Aug;2(8):765-76. doi: 10.1158/2326-6066.CIR-13-0190. Epub 2014 Apr 29.

7.

Mobilization of viable tumor cells into the circulation during radiation therapy.

Martin OA, Anderson RL, Russell PA, Cox RA, Ivashkevich A, Swierczak A, Doherty JP, Jacobs DH, Smith J, Siva S, Daly PE, Ball DL, Martin RF, MacManus MP.

Int J Radiat Oncol Biol Phys. 2014 Feb 1;88(2):395-403. doi: 10.1016/j.ijrobp.2013.10.033. Epub 2013 Dec 5.

PMID:
24315565
8.
9.

Activation of purinergic receptors induces proliferation and neuronal differentiation in Swiss Webster mouse olfactory epithelium.

Jia C, Doherty JP, Crudgington S, Hegg CC.

Neuroscience. 2009 Sep 29;163(1):120-8. doi: 10.1016/j.neuroscience.2009.06.040. Epub 2009 Jun 23.

10.

Hsp72 inhibits apoptosis upstream of the mitochondria and not through interactions with Apaf-1.

Steel R, Doherty JP, Buzzard K, Clemons N, Hawkins CJ, Anderson RL.

J Biol Chem. 2004 Dec 3;279(49):51490-9. Epub 2004 Sep 15.

11.

China's one-child policy: the economic choices and consequences faced by pregnant women.

Doherty JP, Norton EC, Veney JE.

Soc Sci Med. 2001 Mar;52(5):745-61.

PMID:
11218178
12.

DNA methylation in the promoter region of the p16 (CDKN2/MTS-1/INK4A) gene in human breast tumours.

Woodcock DM, Linsenmeyer ME, Doherty JP, Warren WD.

Br J Cancer. 1999 Jan;79(2):251-6.

13.

Asymmetric methylation in the hypermethylated CpG promoter region of the human L1 retrotransposon.

Woodcock DM, Lawler CB, Linsenmeyer ME, Doherty JP, Warren WD.

J Biol Chem. 1997 Mar 21;272(12):7810-6.

14.

Adverse events associated with mefloquine. Study in returned travellers confirms authors' findings.

Corbett EL, Doherty JP, Behrens RH.

BMJ. 1996 Dec 14;313(7071):1552. No abstract available.

15.

A sensitive RNase protection assay to detect transcripts from potentially functional human endogenous L1 retrotransposons.

Woodcock DM, Williamson MR, Doherty JP.

Biochem Biophys Res Commun. 1996 May 15;222(2):460-5.

PMID:
8670227
16.

Glassy solutions of the Kardar-Parisi-Zhang equation.

Moore MA, Blum T, Doherty JP, Marsili M, Bouchaud JP, Claudin P.

Phys Rev Lett. 1995 May 22;74(21):4257-4260. No abstract available.

PMID:
10058455
17.

Generalizations of the Kardar-Parisi-Zhang equation.

Doherty JP, Moore MA, Kim JM, Bray AJ.

Phys Rev Lett. 1994 Mar 28;72(13):2041-2044. No abstract available.

PMID:
10055773
18.

Escherichia coli host strains SURE and SRB fail to preserve a palindrome cloned in lambda phage: improved alternate host strains.

Doherty JP, Lindeman R, Trent RJ, Graham MW, Woodcock DM.

Gene. 1993 Feb 14;124(1):29-35.

PMID:
8440479
19.

Modified-cytosine restriction-system-induced recombinant cloning artefacts in Escherichia coli.

Williamson MR, Doherty JP, Woodcock DM.

Gene. 1993 Feb 14;124(1):37-44.

PMID:
8382656
20.

A sizing artifact of DNA restriction fragments with unusually long single-stranded termini.

Woodcock DM, Crowther PJ, Doherty JP, Linsenmeyer ME, Krüger DH.

Gene. 1991 Jun 15;102(1):79-81.

PMID:
1650735
22.

Effects of mcr restriction of methylated CpG islands of the L1 transposons during packaging and plating stages of mammalian genomic library construction.

Doherty JP, Graham MW, Linsenmeyer ME, Crowther PJ, Williamson M, Woodcock DM.

Gene. 1991 Feb 1;98(1):77-82.

PMID:
1849497
23.

Expression of two conserved leptospiral antigens in Escherichia coli.

Doherty JP, Adler B, Rood JI, Billington SJ, Faine S.

J Med Microbiol. 1989 Feb;28(2):143-9.

PMID:
2644433
24.

A conspiracy for life.

Doherty JP.

Health Prog. 1988 Jun;69(5):110. No abstract available.

PMID:
10287452
25.

AIDS: one psychosocial response.

Doherty JP.

QRB Qual Rev Bull. 1986 Aug;12(8):295-7.

PMID:
3093953

Supplemental Content

Loading ...
Support Center